New publication demonstrates potential of Naxus® for alleviating IBD through gut microbiota alterations and increased butyrate production in mice
Press release
In the present study published in Molecules, the leading international, peer-reviewed, open-access journal of chemistry, the authors evaluated the potential positive effects of arabinoxylans (AX) contained in Naxus® on T-cell-dependent colitis. The findings of the study showed that Naxus® was able to induce peripherally induced Treg (pTreg) cells in the colon. This resulted in a reduction of T-cell-dependent chronic colitis due to the increased levels of butyrate-producing bacteria and luminal butyrate levels. These findings implicate that there could be a role for Naxus® in the treatment of inflammatory bowel disease.
Naxus®: a product researched and developed by BioActor
NAXUS®, an arabinoxylan extract obtained from the endosperm of wheat and is known for its beneficial health effects.
Wheat arabinoxylans (AX) are, in turn, a type of non-starch polysaccharide found in the cell walls of wheat grains. AXs are typically composed of a linear β (1-4)-linked xylan backbone with side residues of a-1-arabinofuranose units attached via α-(1-3) and/or α-(1-2) linkage.
Several clinical studies have shown that Naxus® is a powerful and well-tolerated prebiotic which induces a positive effect on the immune system and blood sugar levels by modulating the microbiome composition and Short Chain Fatty Acids (SCFA) production.
Effect of Naxus® on the Gut Microbiota Composition and Colonic Regulatory T Cells: in vitro and in vivo study
Introduction
The study was conducted by the group of Seita Chudan and the groups’ aim was to to understand the effect of wheat-derived arabinoxylan on gut microbiota, colonic regulatory T cells (Tregs) which are a specific subset of T cells that suppresses the immune response, and experimental colitis, this way, discussing the importance of a healthy gut microbiota and its connection to immune function and disease.
Many studies have looked at how AXs from wheat affect the bacteria and compounds in our gut, as well as a type of antibody present in the immune system called Immunoglobulin A (IgA).
However, not many studies have shown how AX might be helpful in treating Inflammatory Bowel Disease (IBD), a condition that is characterized by inflammation of the GI tract. One recent study has looked at how AX might help with a type of IBD called DSS-induced colitis, but it’s still unclear if AX can prevent colitis.
Therefore, it is important to understand how wheat AXs affect the immune system and colitis, particularly in cases caused by the acquired immune system.
Methods
In this study, healthy and chronic colitis model mice were fed with food containing cellulose or Naxus® for 2–6 weeks and subjected to subsequent analysis of the gut microbiota composition and the number of colonic regulatory T cells in both groups.
Results
The results of this study indicate that Naxus® promotes the development of colonic pTregs and helps to reduce T-cell-dependent chronic colitis. The number of colonic regulatory T cells was significantly higher in the Naxus® group compared to the control group. These positive effects may be due to changes in the gut microbiota and increased levels of short-chain fatty acids (SCFAs), especially butyrate.
Table 1: Quantification of fecal SCFA in mice fed with food containing CE (cellulose) or AX (n = 8)
Butyrate is produced by certain bacteria in the Lachnospiraceae family, such as Eubacterium and Roseburia spp., Increases in Lachnospiraceae bacteria were linked to an increase in fecal butyrate concentration and a greater number of colonic Tregs in the Naxus®-fed mice.
In a T cell transfer model of chronic colitis, Naxus® was found to improve body weight loss and reduce colonic tissue inflammation, possibly through Treg induction. In addition, in this colitis model, wheat-derived arabinoxylan decreased TNFα production from type 1 helper T cells.
Therefore, Naxus® could be a useful prebiotic for preventing colitis by modifying the gut microbiota and shifting the metabolite production more towards butyrate.
Conclusion
This study shows that Naxus® has positive effects in a mouse model of chronic colitis. These improvements are linked to the alterations in the gut microenvironment by regulating the gut microbiota composition and increasing the number of colonic regulatory T cells, which could have implications for the prevention and treatment of inflammatory bowel disease and other immune-related diseases.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact via info@bioactor.com for more information on the possibilities Naxus® has to offer.
Further information can also be found on: www.naxus.nl.
